ClinicalTrials.gg
CompletedNCT00329160Updated Aug 31, 2011Results posted

Rosuvastatin in the Long-term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease

A Phase 4 interventional study of Rosuvastatin and HMG CoA inhibitor in Hypercholesteremia, sponsored by AstraZeneca. Completed at 27 sites in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-08-31.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
214
Allocation
Non-randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 59 studies testing rosuvastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. rosuvastatin · Hypercholesterolemia.

Enrollment
28th of 57
214 · median 203
Started
2005
with 1 other
Phase 4
15 of 59
none open now
Registered
8th of 59
by date
Lead sponsor
25 of 59
AstraZeneca

Among the 59 studies testing rosuvastatin in Hypercholesterolemia, this one is the 28th largest by enrollment of the 57 interventional ones that give a count, is one of 2 that started in 2005, is one of 15 in phase 4, and was the 8th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

None of the 59 studies testing rosuvastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 59 studies testing rosuvastatin in Hypercholesterolemia as a file.
02

Study summary

The primary objective of this study is to evaluate that 76 weeks of treatment with rosuvastatin calcium 2.5-20 mg results in no progression of coronary artery atherosclerotic volume as measured by intravascular ultrasonography (IVUS) imaging in hypercholesterolaemic subjects with coronary heart disease (CHD).

03

Conditions studied

  • Hypercholesteremia
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed written ,
  • 20 to 75 years old,
  • Plan to undergo coronary angiography (CAG) or Percutaneous coronary intervention (PCI) and LDL-C ≥ 140 mg/dL (untreated patients) or LDL-C ≥ 100 mg/dL (treated patients)

Exclusion criteria

Exclusion Criteria:

  • Acute myocardial infarction within 72 hours after the onset,
  • Heart failure of (NYHA) Class III or above,
  • Serious arrhythmia,
  • Being treated with LDL-apheresis
  • History of serious reaction or to other HMG-CoA reductase inhibitors.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
214 participants (actual)

Interventions

  • 2.5-20 mg

  • DrugHMG CoA inhibitor

    3-hydroxy-3-methylglutaryl-coenzyme A

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline (Before the Start of Rosuvastatin Treatment) to Week 76 in the Plaque Volume (PV)

    Plaque volume will be assessed by volumetric analysis with the echoPlaque2 system (Indec Systems Inc). Baseline and follow-up IVUS images will be reviewed side-by-side on a display, and the target segment selected. The target segment to be monitored will be determined in a non-PCI site (\>5 mm proximal or distal to the PCI site) with a reproducible index such as side branches, calcifications, or stent edges.

    Time frame: Baseline and 76 weeks

Secondary outcomes

  1. Change From Baseline to Week 76 in Plaque Volume (PV) in the Target Lesion

    Target Lesion indicates Coronary plaque composition of culprit lesions.

    Time frame: Baseline - 76Weeks

  2. Percent Change From Baseline to Specified Measurement Time Points in Low-density Lipoprotein (LDL-C)

    Time frame: Baseline - 76Weeks

  3. Percent Change in High-sensitivity C-reactive Protein (HS-CRP) From Baseline to Specified Measurement Time Points

    Time frame: Baseline - 76Weeks

07

Results

Posted Jul 15, 2011
Limitations and caveats
Because there was no placebo arm the net effect of rosuvastatin was not clarified. This study examined only single measurable plaques, which might not represent pan-coronary nature of plaque.

Participant flow

Participant flow — Overall Study
MilestoneRosuvastatin
Started214
Observation period214
Treatment period214
Completed126
Not completed88
Withdrew: Adverse event27
Withdrew: Withdrawal by subject13
Withdrew: Protocol violation2
Withdrew: Did not receive study drug1
Withdrew: Incomplete ivus45

Outcome measures

PrimaryPercent Change From Baseline (Before the Start of Rosuvastatin Treatment) to Week 76 in the Plaque Volume (PV)

Plaque volume will be assessed by volumetric analysis with the echoPlaque2 system (Indec Systems Inc). Baseline and follow-up IVUS images will be reviewed side-by-side on a display, and the target segment selected. The target segment to be monitored will be determined in a non-PCI site (\>5 mm proximal or distal to the PCI site) with a reproducible index such as side branches, calcifications, or stent edges.

Time frame:
Baseline and 76 weeks
Reported as:
Mean · Percent Change
Percent Change From Baseline (Before the Start of Rosuvastatin Treatment) to Week 76 in the Plaque Volume (PV)
Percent ChangeRosuvastatin
Percent Change From Baseline (Before the Start of Rosuvastatin Treatment) to Week 76 in the Plaque Volume (PV)14.1 ± -5.066
SecondaryChange From Baseline to Week 76 in Plaque Volume (PV) in the Target Lesion

Target Lesion indicates Coronary plaque composition of culprit lesions.

Time frame:
Baseline - 76Weeks
Reported as:
Mean · mg/dL
Change From Baseline to Week 76 in Plaque Volume (PV) in the Target Lesion
mg/dLRosuvastatin
Change From Baseline to Week 76 in Plaque Volume (PV) in the Target Lesion12.074 ± -5.259
SecondaryPercent Change From Baseline to Specified Measurement Time Points in Low-density Lipoprotein (LDL-C)
Time frame:
Baseline - 76Weeks
Reported as:
Mean · Percent change
Percent Change From Baseline to Specified Measurement Time Points in Low-density Lipoprotein (LDL-C)
Percent changeRosuvastatin
Percent Change From Baseline to Specified Measurement Time Points in Low-density Lipoprotein (LDL-C)16.9 ± -38.6
SecondaryPercent Change in High-sensitivity C-reactive Protein (HS-CRP) From Baseline to Specified Measurement Time Points
Time frame:
Baseline - 76Weeks
Reported as:
Mean · Percent change
Percent Change in High-sensitivity C-reactive Protein (HS-CRP) From Baseline to Specified Measurement Time Points
Percent changeRosuvastatin
Percent Change in High-sensitivity C-reactive Protein (HS-CRP) From Baseline to Specified Measurement Time Points18.1 ± 291.3

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rosuvastatin—98/213 (46%)588/214 (274.8%)
Most frequent serious events
Showing 10 of 61
Most frequent serious events
EventRosuvastatin
Coronary Artery StenosisCardiac disorders21/213
Angina PectorisCardiac disorders7/213
Cardiac Failure CongestiveCardiac disorders2/213
Prinzmetal AnginaCardiac disorders2/213
PyrexiaGeneral disorders2/213
Hepatic Function AbnormalHepatobiliary disorders2/213
Coronary Artery RestenosisInjury, poisoning and procedural complications2/213
In-Stent Coronary Artery RestenosisInjury, poisoning and procedural complications2/213
Subdural HaematomaInjury, poisoning and procedural complications2/213
C-Reactive Protein IncreasedInjury, poisoning and procedural complications2/213
Most frequent other events
Showing 10 of 27
Most frequent other events
EventRosuvastatin
NasopharyngitisInfections and infestations69/214
Gamma-Glutamyltransferase IncreasedInfections and infestations48/214
Blood Creatine Phosphokinase IncreasedInfections and infestations43/214
Alanine Aminotransferase IncreasedInfections and infestations38/214
Blood Urine PresentInfections and infestations33/214
Protein Urine PresentInfections and infestations31/214
Aspartate Aminotransferase IncreasedInfections and infestations28/214
Glucose Urine PresentInfections and infestations28/214
Blood Pressure IncreasedInfections and infestations22/214
Blood Alkaline Phosphatase IncreasedInfections and infestations20/214

Baseline characteristics

Age Continuous
Age Continuous(years)Rosuvastatin
Years62.6 ± 7.7
Sex: Female, Male
Sex: Female, Male(Participants)Rosuvastatin
Female30
Male96
08

Study locations

27 sites
  • Research Site
    Gifu, Japan
  • Research Site
    Hamada, Japan
  • Research Site
    Hiroshima, Japan
  • Research Site
    Ichinomiya, Japan
  • Research Site
    Inba-mura, Japan
  • Research Site
    Izumisano, Japan
  • Research Site
    Izumi, Japan
  • Research Site
    Izumo, Japan
  • Research Site
    Kagoshima, Japan
  • Research Site
    Kanazawa, Japan
  • Research Site
    Kasuga, Japan
  • Research Site
    Kobe, Japan
  • Research Site
    Komaki, Japan
  • Research Site
    Konan-cho, Japan
  • Research Site
    Kumamoto, Japan
  • Research Site
    Kurume, Japan
  • Research Site
    Kyoto, Japan
  • Research Site
    Omiya, Japan
  • Research Site
    Osaka, Japan
  • Research Site
    Sapporo, Japan
  • Research Site
    Shinjo, Japan
  • Research Site
    Shunan, Japan
  • Research Site
    Suita, Japan
  • Research Site
    Tokyo, Japan
  • Research Site
    Ube, Japan
  • Research Site
    Yamaguchi, Japan
  • Research Site
    Yokohama, Japan
09

References and documents

Publications

  • Daida H, Takayama T, Hiro T, Yamagishi M, Hirayama A, Saito S, Yamaguchi T, Matsuzaki M; COSMOS Investigators. High HbA1c levels correlate with reduced plaque regression during statin treatment in patients with stable coronary artery disease: results of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Cardiovasc Diabetol. 2012 Jul 25;11:87. doi: 10.1186/1475-2840-11-87. PubMed 22831708 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2005, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2011, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2006
First posted
May 24, 2006
Start
Oct 2005
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results first posted
Jul 15, 2011
Last update
Aug 31, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00329160
Lead sponsor
AstraZeneca
Collaborators
Shionogi
Responsible party
Sponsor
First posted
May 24, 2006
Start date
Oct 2005
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Jul 15, 2011
Last update
Aug 31, 2011

Study contacts

Masunori Matsuzaki, MD
principal investigator · Yamaguchi University Hospital
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion